Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Case Report Names Drospirenone-Containing Hormonal Contraceptive as “Only Associated Risk Factor” in Development of Blood Clot

Posted in Yaz, Yasmin & Ocella

A report published in 2006 in the medical journal Clinical and Applied Thombosis/Hemostasis reviews the case of a woman, aged 36 years, who came under the care of Dr. Y. Mira, presenting deep venous thromboses (blood clots) in the “left jugular and subclavian” veins.[1]  Blood clots are a very serious occurrence, possibly leading to heart attack or stroke.

Because the patient had no family history of blood clotting,[2] and demonstrated no other risk factors, doctors concluded that the patient’s use of “Yazmin®,” a hormonal contraceptive containing drospirenone, known to place its users at a higher risk for the development of blood clots than other hormonal contraceptives, “was the only associated risk factor…,”[3] and likely caused the event.

Other oral contraceptives that contain drospirenone, and thus place women at a higher risk for blood clots, are YAZ®, Beyaz®, and Safyral®.

While this article did not describe in detail the biochemistry of how drospirenone causes blood clots, from it we learn that this chemical is known by the medical research community to be more dangerous than its “peer” chemicals, if you will, though it does not demonstrate increased efficacy in pregnancy prevention.  As such, Dr. Mira’s piece may be used by in a Yaz lawsuit to help provide evidence that the drugs Yaz®, Beyaz®, Safyal®, and Yazmin®, each place users at an unnecessarily high risk for serious adverse health effects.


[1] “Ethinylestradiol/drospirenone Deep vein thrombosis: case report.” Case Report. Reactions Weekly 15 May 2010, No. 1301 © 2010 Adis Data Information BV; p. 23

[2] Ibid

[3] Mira, Y. (et al.)   “Is Yasmin as safe as other contraceptive pills?” Clinical and Applied Thrombosis/Hemostasis 12:378-379, No. 3, Jul 2006.